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Abstract
Background: Superinfection with drug resistant HIV strains could potentially contribute to compromised therapy in
patients initially infected with drug-sensitive virus and receiving antiretroviral therapy. To investigate the importance
of this potential route to drug resistance, we developed a bioinformatics pipeline to detect superinfection from
routinely collected genotyping data, and assessed whether superinfection contributed to increased drug resistance in
a large European cohort of viremic, drug treated patients.
Methods: We used sequence data from routine genotypic tests spanning the protease and partial reverse
transcriptase regions in the Virolab and EuResist databases that collated data from five European countries.
Superinfection was indicated when sequences of a patient failed to cluster together in phylogenetic trees constructed
with selected sets of control sequences. A subset of the indicated cases was validated by re-sequencing pol and env
regions from the original samples.
Results: 4425 patients had at least two sequences in the database, with a total of 13816 distinct sequence entries
(of which 86% belonged to subtype B). We identified 107 patients with phylogenetic evidence for superinfection. In
14 of these cases, we analyzed newly amplified sequences from the original samples for validation purposes: only 2
cases were verified as superinfections in the repeated analyses, the other 12 cases turned out to involve sample or
sequence misidentification. Resistance to drugs used at the time of strain replacement did not change in these two
patients. A third case could not be validated by re-sequencing, but was supported as superinfection by an
intermediate sequence with high degenerate base pair count within the time frame of strain switching. Drug
resistance increased in this single patient.
Conclusions: Routine genotyping data are informative for the detection of HIV superinfection; however, most cases
of non-monophyletic clustering in patient phylogenies arise from sample or sequence mix-up rather than from
superinfection, which emphasizes the importance of validation. Non-transient superinfection was rare in our mainly
treatment experienced cohort, and we found a single case of possible transmitted drug resistance by this route. We
therefore conclude that in our large cohort, superinfection with drug resistant HIV did not compromise the efficiency
of antiretroviral treatment.
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Background
Superinfection occurs when a patient with established
HIV infection is infected with a second viral strain [1],
and may have epidemiological and clinical implications in
the HIV pandemic. It allows for the recombination of two
distinct lineages [2], which may facilitate viral evolution
[3-6]. It can also lead to the loss of viral control, if a super-
infecting viral strain escapes CD8 immune responses [7],
and can accelerate disease progression [8]. Furthermore,
an established drug sensitive HIV strain can be invaded by
superinfection with a drug resistant virus [9].
Finding at least two distinct viral strains in the samples
of the same patient that have not evolved by divergence
within that patient implies superinfection. While such a
situation may also arise by simultaneous transmission of
two distinct viral strains from the same infecting source
[1], considering the low number of transmitted viruses
[10] such simultaneous transmissions are probably rare,
and we assume that most cases of “dual infections” reflect
superinfection.
Possible transient superinfections present a further con-
founding factor for the estimation of the prevalence of
superinfection [2]. If the second viral strain is able to
grow to low levels only, or it is lost after a short transient
period, superinfection may remain undetected with low-
sensitivity population sequencing or infrequent sampling.
Differences in the sampling strategy may thus explain the
large variance in the published estimates of the prevalence
of superinfection. Some studies found a low (<5%) preva-
lence of superinfection either by population sequencing
(e.g., [11]) or deep sequencing (e.g., [12,13]). Other studies
estimated much higher prevalence, e.g., one study identi-
fied 23 superinfections in 58 patients of a US cohort by
clonal sequencing of several samples per patient [2]. Jur-
riaans et al. identified two cases in a study population of
14 patients [14], and another study reported five cases in
a group of 14 high risk women from Kenya [15].
It is unclear whether an established infection decreases
the chance of another virus to invade [16,17]. However,
effective antiretroviral treatment (ART) reduces the virus
load to very low levels, which results in the gradual
restoration of target cell levels and the waning of anti-HIV
immunity [18]. This could set the stage for the invasion
of a virus that can tolerate the drugs. Superinfection of
patients under ART could therefore potentially constitute
an important route in the spread of drug resistance muta-
tions, in addition to primary mutation and transmission.
In this study we screened for superinfection a large
population of patients, most of whom were under ART
and had low, but detectable viral loads. While ongoing
ART was probably able to prevent superinfection with
virus strains susceptible to the current treatment of each
patient, this population was ideal for testing whether
superinfection is a major contributor to the spread of
highly drug resistant HIV that could compromise ther-
apy in treated patients. ART imposes a constant selection
pressure that favours highly drug resistant viruses that can
grow under these conditions, and the loss of viral con-
trol due to superinfection by a resistant virus would likely
result in repeated resistance testing, which would enable
the detection of the event in our database. Our detection
methods enabled us to detect non-transient superinfec-
tion where the invading strain outgrows and replaces the
resident viral strain: this is the scenario that has practical
relevance for drug treatment. Our primary goals were to
estimate the frequency of strain replacement (“successful
superinfection”) in the Virolab and EuResist collaborative
European databases, and to assess whether superinfec-
tion contributes to virologic failure due to acquired drug
resistance. We based our analyses on routinely collected
genotypic data, which have been shown to allow for the
detection of superinfection [19].
Methods
Ethics statements
All study participants provided written informed con-
sents. Ethical approvals were obtained from the local
ethical committees: the Regional Ethical Review Board
in Stockholm (2005/1167–31/3), the Ethics Committee of
the Catholic University of Rome, the Ethics Committee
of the University Clinic Cologne, the Belgian Ethical
Committee (B32220072107) and the Ethical Committee of
the Spedali Civili di Brescia. The study was conducted in
accordance with the declaration of Helsinki.
Patients and sequences
We analyzed the joint database of the EuResist and Virolab
consortia, which included clinical and demographic data,
treatment history and sequence data from genotyping
assays collected at clinical centres in Belgium, Germany,
Italy, Spain and Sweden. Data from the individual data
centres were stored in independent instances of the
RegaDB data scheme [20] and virtualized into a single col-
laborative database. We included data from patients from
whom sequences were available from a minimum of two
distinct time points. We obtained 13816 sequences from
4425 patients who had at least two sequences from dis-
tinct time points in the Virolab/EuResist database. The
sequences spanned the PR and partial RT regions of the
pol gene of the viral genome [21,22].
Phylogenetic software and substitution model
We used RAxML v7.2 [23] and MrBayes v3.1.8 [24] to
reconstruct phylogenetic trees. A GTR substitutionmodel
was assumed in both cases (based on the advised proto-
col for RAxML, and also for MrBayes to obtain consistent
results). In the RAxML analyses, branch support values
were computed based on bootstrap replicates (-autoMR
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method of RAxML), while posterior probabilities were
used with MrBayes. In the case of MrBayes 10,000,000
generations were simulated on 4 chains of 3 simultane-
ous runs, with 10,000 steps discarded as burnins. We used
PAUP [25] to calculate maximum likelihood sequence
distances under the GTR model without building a phylo-
genetic tree.
Subtyping
HIV subtype was determined with the Rega v2 subtyping
tool [26,27].
Detecting superinfection
To decide whether a patient had been infected by two dis-
tinct viral strains we constructed a phylogenetic tree with
all sequences of the patient and a fixed number of control
sequences. We considered an individual to be superin-
fected if his/her own HIV sequences failed to form a
monophyletic cluster in the tree, with at least a thresh-
old number of control sequences clustering together
with the sequences of the patient (see below Evaluating
Phylogenetic Trees). Following the procedure in [28]
(see Figure 1), control sequences were selected by a
BLAST search [29] using a local BLAST database assem-
bled from the set of all available HIV sequences that
spanned the same genomic region (partial pol or env)
(see below Local BLAST database). We constructed a
control sequence set for each patient by submitting each
sequence of the patient to a BLAST search and selecting
from the BLAST result list (ordered in descending simi-
larity score) a fixed number of the most similar sequences
of appropriate length. All sequences of the patient were
pooled in a single analysis and topped up to a fixed total
number (e.g. 150) by adding the same number of matched
Figure 1 Scheme of the analysis pipeline for detecting HIV dual
infection.We assembled a control sequence set for each patient by
selecting, from a large sequence dataset, the highest ranking BLAST
results (closest sequence matches) to each sequence of the patient,
such that the total set included 150 sequences, and each sequence of
the patient was matched with the same number of control
sequences. Phylogenetic trees were then constructed and analyzed
for each sequence set, one tree per patient.
control sequences per patient sequence. The set of control
sequences did not contain duplications. Individual phy-
logenetic trees per patient were then constructed using
the patient strains and its control set, and evaluated as
described below.
Local BLAST database We downloaded 44244 par-
tial HIV-1 B sequences from the Los Alamos HIV
Database (http://www.hiv.lanl.gov/) that spanned HXB2
coordinates 2253-3290, and merged them with 26130
sequences spanning the same region in the Virolab/
EUResist database. Note that the latter count included
also sequences from patients who were part of the
Virolab/EUResist database but were not eligible for the
detection of superinfection, because only one sequence
was available from them. Sequence alignment was done by
Muscle v3.8.31 [30]. Pol sequences were aligned byMuscle
in batches of 1000 sequences, then these partial align-
ments were merged using the HXB2 reference sequence
as a guide. Codons associated with drug resistance were
removed based on the Stanford HIV Drug Resistance
Database (as of 2009) [31]; gap-stripping (with a thresh-
old of 50%) removed all insertions relative to the reference
sequence. A local BLAST database was compiled from
the alignment. Another BLAST database was built from
publicly available env sequences (13725 sequences down-
loaded from the Los Alamos HIV Database) for the val-
idation procedure that involved also env. env sequence
alignment was constructed with translated amino acid
sequences using Muscle v3.8.31 [30]. Sequence transla-
tion was done by transeq [32]; frame-shifts were corrected
manually.
Evaluating phylogenetic trees for superinfection We
developed Ruby scripts (available in Additional file 1)
to evaluate whether the sequences of a patient form a
monophyletic cluster in the phylogenetic tree constructed
from the HIV sequences of the patient and the control
sequences selected by BLAST. We collapsed all internal
nodes that had low support to polytomic nodes: nodes
with a minimum bootstrap support value of 60 or a min-
imum posterior probability of 0.95 were retained in the
trees constructed with RAxML and MrBayes, respec-
tively. A tree was considered to reflect putative super-
infection when i) at least two sequences of the patient
clustered closer with control sequences than with each
other (Figure 2) and ii) the size of the minimal subtree
that contained all sequences of the patient was larger than
50, based on Additional file 2. We applied the strict first
criterion to ensure that weakly supported misclustered
sequences could not induce a false positive finding. By
applying the second criterion we hypothesized that a small
number of control sequences in the subtree is more likely
to reflect a transmission cluster (possibly originating from











Figure 2 Scheme of phylogenetic trees representing
superinfection or transmission cluster. Orange nodes denote
sequences from the individual under examination; grey nodes
represent control sequences. Panel A illustrates a case of
superinfection, while Panel B illustrates a transmission cluster. The
sequences of the patient under study fail to form a monophyletic
cluster in both cases; however, the number of control sequences in
the smallest subtree that includes the sequences of the patient tends
to be much greater in the case of superinfection (see main text).
the patient under study) than a genuine case of super-
infection. The distribution of cluster sizes is depicted in
Additional file 2. The strong bimodality of the distribution
indicated a gap between potential transmission clusters
and potential superinfections, with an obvious cut-off at a
cluster size of 50 control sequences. We therefore classi-
fied the cases with <50 control sequences in the minimal
subtree as putative transmission clusters. Some such cases
may also have arisen if sequences of the same patient
occurred in the database under different identifiers, either
from sample mix-up or from GenBank. This additional
criterion also helped to minimise false positive results
arising from ambiguously clustered sequences.
Experimental validation of putative superinfection cases
To validate several cases of putative superinfection, we
performed fresh sample amplification and population
sequencing on selected archived samples, involving either
the same pol region as in the original sequence data, or the
C2-C4 region of env (HXB2 positions 7021-7560) from the
samples dating from just before and just after the puta-
tive event of superinfection [9,33-35]. The newly obtained
sequences were then checked for superinfection by the
same analysis pipeline as in the original analyses. To assess
whether the newly obtained sequences cluster together
with (any of) the original sequences of the patient, we
included also the original sequences in the alignment used
to infer the phylogenetic trees.
Quantitation of drug resistance (drug susceptibility scores)
We used the Stanford HIVdb Sequence Analysis web ser-
vice (http://hivdb.stanford.edu, [31]) for the estimation
of drug resistance. We report Stanford resistance classes
based on Stanford Scores (0-9: S; 10-14: PL; 15-29: LL;
30-59: R ; 60+: HR). A higher score means a more resis-
tant virus strain, with weaker virologic response to drug
treatment.
Results
Based on our eligibility criteria 13816 sequences from
4425 patients were retained for the analysis. Most
sequences spanned part of pol (protease (PR) and partial
reverse transcriptase (RT) genes), with an average length
of 1026 nucleotides. The median sequence count was 2
(range: 2-29) per patient.
3653 participants received ART during the follow-up
period. For 772 patients treatment information was not
available. 1123 individuals (25%) were heterosexual, 910
(20%) men having sex with men, 1000 (22%) intravenous
drug users, 1236 (27%) unknown and 156 (3%) were in
other risk groups. 1308 (29%) individuals were female. For
3878 participants we had access to at least one viral load
measurement, 3552 of those had at least onemeasurement
above 10000 copies/ml. Viral load measurements in the
database had amedian of 3.3 log10 copies/ml (IQR: 1.9-4.4
log10 copies/ml). CD4 measurements in the database had
a median of 349 cells/μl (IQR: 208-521 cells/μl). The first
CD4 or viral load test had a median date of 1997-11-17
(IQR: 1995-01-30 - 2001-10-15). Median age at the earli-
est data point was 34.8 years (IQR: 29.3 - 40.9 years). Time
between the earliest and latest sample of a patient had a
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median of 756 days (IQR: 367-1497 days). 86% of the HIV
sequences belonged to subtype B (Additional file 3), and
86% (3814/4425) of the patients were infected with this
subtype. 19.2% (2655/13816) of the sequences were resis-
tant to all three drug classes (PI, NRTI, NNRTI) associated
with the available genomic region, and 28.2% (1250/4425)
of the patients had at least one such sequence, indicating
a highly drug-experienced cohort.
Detection of superinfection based on phylogenetic analysis
The detection method relies on the analysis of phyloge-
netic trees constructed from the sequences of a patient
and a set of control sequences matched to the patient’s
sequences by sequence similarity from a large database
(see below). In such a tree, if the minimal subtree that
includes all sequences of an individual includes also one
or more control sequences, then either i) the most recent
common ancestor of the sequences was not located in
the patient, which indicates superinfection with a dis-
tinct lineage (Figure 2A) or ii) the control sequences are
derived from a transmission cluster that originated from
the patient (Figure 2B).
In our analysis we searched for cases of super (or dual)
infection by the following two criteria: first, at least two
sequences of the patient had to form a strongly supported
monophyletic cluster with unrelated control sequences.
That is, at least two strongly supported clusters had
to be present in the tree that each contained at least
one sequence taken from the patient under investiga-
tion, together with control sequences (see Methods, and
Figure 2A). This choice constitutes a stringent criterion
for the polyphyly of the patient’s sequences.
Second, the minimal subtree that contained all
sequences of the patient had to include at least 50 unre-
lated control sequences. Given the sparse sampling of
sequences in the epidemic, transmission clusters are
likely to be represented by small numbers of sequences;
the exact threshold was set based on the distribution of
the cluster sizes (see Methods and Additional file 2). Fur-
thermore, this criterion also excludes false positive results
that arise when a sequence of the same patient is included
in the control set from anonymous or mislabeled records
in the databases.
Building a reliable phylogenetic tree with a very large
number of sequences is computationally intensive. There-
fore we performed a series of preliminary analyses to
optimize the analysis pipeline of phylogeny-based detec-
tion of superinfection in a large number of patients
(see Additional files 4 and 5).
For each of the 4425 patients we built a phylogenetic
tree with a set consisting of a fixed number of control
sequences. We selected the set of control sequences for
each patient from a massive local BLAST database of
70374 sequences such that each sequence of a patient
was matched and grouped with an equal number of simi-
lar sequences (see Methods and Figure 1). We considered
using RAxML [23], a fast and reliable implementation
of the maximum likelihood phylogenetic approach and
MrBayes [24] which implements the much slower but
more exhaustive Bayesian approach. We first performed
exploratory analyses to compare the performance of
Bayesian (MrBayes) and maximum likelihood (RAxML)
methods on a small number (n=170) of patients, and to
calibrate the optimal support thresholds for both meth-
ods and the optimal size of the control sequence set. The
set of 170 patients for the calibration runs was selected by
preliminary analyses detailed in Additional file 4, and was
enriched in putative cases of superinfection.
Based on the benchmarks tests performed on these 170
patients with RAxML and MrBayes we found that the
number of cases identified as non-monophyletic infection
(either superinfection or transmission cluster) declines as
the threshold for branch support is increased; however,
the two methods could be calibrated to identify consis-
tent sets of patients (Table 1). E.g., the subset identified as
non-monophyletic with the widely used threshold of 0.95
posterior probability with MrBayes could be reproduced
using a threshold bootstrap support of 0.6 in RAxML. We
therefore concluded that the faster maximum likelihood
based RAxML method ensured sufficient sensitivity for
our analyses. To find the optimal size of control sequences
in the analyses, we next performed both MrBayes and
RAxML analyses with tree sizes of 20, 50, 150 and 250
sequences on the same subset of the data (170 patients).
There was no apparent gain in the number of suspected
Table 1 Comparison of methods and calibration of
support threshold for cluster based prediction
MB RAxML Intersect RAxML MB RAxML MB
only only sum sum
0.7 0.6 70 2 4 72 74
0.7 0.7 63 2 11 65 74
0.7 0.95 40 2 34 42 74
0.8 0.6 70 2 3 72 73
0.8 0.7 63 2 10 65 73
0.8 0.95 40 2 33 42 73
• 0.95 0.6 69 3 2 72 71
0.95 0.7 62 3 9 65 71
0.95 0.95 40 2 31 42 71
Comparison of results obtained by RAxML and MrBayes at varied thresholds for
branch support or posterior probability used in the collapsing of phylogenetic
trees. Numbers of patients with non-monophyletic sequences for given
threshold values are shown in the cells. Tree size was 150 in all cases (i.e. the tree
was constructed from an alignment of 150 sequences). The analyses were
performed on a set of 170 patients derived from a preliminary analysis and
enriched in superinfection cases. Full circle indicates the choice of parameters
for the final analyses.
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patients with increasing tree size (Additional file 6), and
the identity of the suspected patients was stable across
different tree sizes (Table 2). This indicates that, using
the BLAST based method to select control sequences
from a massive sequence database, relatively small trees
are sufficient to identify the phylogenetic footprint of
superinfection reliably.
Informed by these results, in the final analysis of all 4425
patients, we used RAxML (for faster speed over MrBayes)
with a threshold bootstrap support of 0.6 (to obtain results
consistent with MrBayes and a threshold of 0.95 poste-
rior probability) and a tree size of 150 (which still allowed
fast phylogenetic reconstruction). Thus, each tree was
built from 150 sequences, including all sequences of a sin-
gle patient, and complemented with control sequences to
reach a total number of 150 sequences. The sequences of
201 patients failed to form a within-patient monophyletic
cluster, with control sequences clustering nested within
the patient’s sequences. Out of these, 107 were suspected
for superinfection and in 94 cases the sequences of the
patient belonged to a closely related transmission clus-
ter (size of minimal subtree ≤ 50, see Methods). One of
the 107 putative superinfection cases turned out to be a
false positive arising frommixing the sequence reads from
the patient strain and a lab strain, and was excluded from
further analysis.
Validation
To validate our results, we had the possibility to re-
sequence stored samples from 14 putative superinfection
cases and 4 controls. In the cases of putative superin-
fections, we attempted to analyze pairs of stored sam-
ples dated as close as possible to and spanning the
putative event of superinfection. For two patients, the
original sample after the suspected superinfection event
was not available, we therefore used a sample obtained
shortly after the original sample. We amplified and (re-)
sequenced partial pol in 6 cases, the C2-C4 region of
env in 4 cases, and both regions in 8 cases. Attempts
to amplify sequences for several other cases failed due
to the degradation of old samples. Analyses of the new
sequences confirmed two out of 14 cases of superinfection
(Table 3). In 9 out of 14 putative superinfection cases, the
new pol sequences of the patient formed a monophyletic
cluster, indicating no evidence for superinfecton.
In all of these cases, the new sequences clustered
together closely with one of the original clusters of the
patient, indicating that the original sequence that clus-
tered separately did not come from the patient, but was
involved in sample or sequence mix-up. In three of the
9 cases, the C2-C4 region of env could also be ampli-
fied from the paired samples, and the analyses yielded
consistent results (no evidence for superinfection).
In two cases, only env could be sequenced from both
original samples: the analyses indicated no evidence for
superinfection; this data, however, did not allow us to
determine which of the original pol sequences was erro-
neously recorded for the patient.
Finally, in one case the new analysis found a reduced
number of control sequences in the minimum subtree
of the patient, indicating a probable transmission cluster
of closely related sequences (all from the same country),
rather than superinfection. A re-analysis of the original
sequences of this patient (with the original set of matched
control sequences) by MrBayes confirmed that the initial
RAxML analysis misplaced some of the control sequences
that apparently clustered together with the patient’s own.
Newly amplified env sequences of this patient formed a
monophyletic cluster.
In the two confirmed superinfection cases, the analysis
of both pol and env indicated evidence for superinfec-
tion, although branch support was low for env. From one
of these patients we had only two sequences, i.e., both
the initial and the putative superinfecting strain were
only present in a single sample. This patient had per-
sistent low CD4 count (<50 cells per μL) in the years
preceding and following the inferred superinfection event.
We had 7 sequences from the other patient, of which
Table 2 Comparison of methods and calibrating the size of the phylogenetic tree
RAxML 150 0.6 MrBayes 150 0.95 RAxML 20 0.6 MrBayes 20 0.95 RAxML 250 0.6 RAxML 50 0.6 MrBayes 50 0.95
RAxML 150 0.6 72
MrBayes 150 0.95 69 71
RAxML 20 0.6 67 66 70
MrBayes 20 0.95 61 62 62 63
RAxML 250 0.6 69 67 66 59 71
RAxML 50 0.6 69 66 65 59 67 69
MrBayes 50 0.95 67 68 64 62 65 66 69
The table shows the number of patients indicated with non-monophyletic infection using the settings of both the row and the column header of a cell, from a
preliminary analysis of 170 individuals. Headers show the phylogenetic software used for tree reconstruction, the size of the tree and the support threshold used when
evaluating the trees.
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Table 3 Validation of putative superinfection cases
Patient Origin/Follow-up Sex Risk Sub- Validated Result of Identified Estimated
group types gene validation mixed-up date of
sample event
Case1 -/Spain M HET B,* POL monophyletic 10/26/2000
Case2 Spain/Spain M HET B POL ENV monophyletic 02/19/2004
Case3 Spain/Spain F HET B,G POL ENV monophyletic1 04/19/2004
Case4 Sweden/Sweden M MSM B POL ENV monophyletic 05/05/2004
Case5 Eritrea/Sweden M NA C ENV monophyletic2
Case6 -/Belgium M HET * ENV monophyletic
Case7 -/Italy M MSM *,B POL monophyletic 01/25/2006
Case8 Italy/Italy M VERT B POL ENV cluster of closely related samples
Case9 -/Italy M NA B POL ENV monophyletic 19/07/1999
Case10 -/Italy M NA B POL monophyletic 04/20/1998
Case11 Italy/Italy F HET B POL monophyletic 09/10/1997
Case12 Italy/Italy F IVDU B POL monophyletic 11/24/1998
• Case13 -/Italy F HET B POL ENV POL: non monophyletic ENV: non
monophyletic but fails criteria (low
support)
Jan 98- May 98
•Case14 -/Italy M IVDU B POL ENV POL: non monophyletic ENV: non
monophyletic but fails criteria (low
support)
Nov 97- Nov 98
Control1 Spain/Spain M MSM * POL ENV monophyletic
Control2 Spain/Spain M HET B POL ENV monophyletic
Control3 -/Spain M HET * ENV monophyletic
Control4 -/Belgium M HET CRF 02_AG ENV monophyletic
Results of the validation of 14 cases of putative superinfection and 4 controls. Samples where thawed, amplified and pol and env regions where sequenced as
described in the Methods. Full circles indicate confirmed superinfection cases. Notes: 1the sample before the superinfection event was unavailable, an alternative was
used; 2neither of the original samples were available and two alternatives were used. An asterisk (*) indicates that subtype could not be determined uniquely.
Abbreviations: IVDU - intravenous drug users; HET - heterosexuals; MSM - men having sex with men; VERT - vertical transmission; NA - unknown; F - Female; M - Male.
6 clustered together. A single sequence represented a
divergent lineage, and it was both preceded and followed
by samples that yielded sequences of the larger cluster,
which probably indicates a case of transient superinfec-
tion. There was an abrupt drop in the CD4 count (from
430 to 125 cells per μL) in the one-year interval between
the two samples that indicated the strain switching, and
this loss was not restored when the original strain re-
appeared in the subsequent sample points. Importantly,
strain switching (superinfection) was not associated with
increasing drug resistance scores against the drugs that
were administered at the time of strain switching in
either of the patients (Table 4). Clinical and demographic
parameters, treatment history and drug susceptibility
scores of these two patients are shown in Additional
file 7.
None of the four control cases yielded evidence for
superinfection. Sequence alignments of both the origi-
nal and the newly generated sequences of the 18 patients
involved in the validation procedure and their control
sequences are attached in Additional file 8.
Detection based on degenerate base pair count
Finally, following the method of Cornelissen et al. [33]
we also counted the number of degenerate base codes
(DBC) in all available sequences. A high DBC count may
indicate that a mixture of two divergent virus strains was
present in the patient at the time of sampling: using clonal
sequencing, Cornelissen et al. found that a DBC count of
45 in routine genotyping sequences (such as used in the
present study) is associated with dual infection in about
73% of the cases. In our study, 79 patients had at least
one sequence with a DBC count higher than or equal to
45 (5 patients had two, and one patient had three such
sequences). Of these 79 patients, six were suspected for
superinfection based on our phylogenetic analysis with
RAxML. One case (Case2 in Table 3) was subjected to
validation, and the result indicated sample mix-up as the
source of the false positive superinfection signal: notably,
the sample yielding the high DBC count was the sample
involved in a mix-up. The analyses of both pol and env
showed strong monophyletic clustering with the newly
amplified sequences of this patient.
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Table 4 Drug resistance interpretation for the three superinfection cases
Regime Case13 Case14 DBC+
Resident strain Superinfecting strain Resident strain Superinfecting strain Resident strain Superinfecting strain
3TC HR HR PL S •S HR
ABC HR LL R S S •HR
ATV/r S LL S S S S
AZT HR R •HR •LL •PL HR
D4T •HR •R HR PL LL •HR
DDI •HR PL •R •S PL HR
DLV S S S S S S
DRV/r S S S S S S
EFV S •S S S S S
ETR S S S S S S
EVG S S S S S S
FPV/r S LL S S S S
FTC HR HR PL S S HR
IDV/r S R •S •S S S
LPV/r S PL S S S S
NFV •S •HR S S S S
NVP S S S S S S
RAL S S S S S S
SQV/r S R S S S S
TDF R PL R S PL •LL
TPV/r S S S S S S
Drug resistance (based on http://hivdb.stanford.edu) in the two patients with validated superinfection and the patient suspected for superinfection based on high
degenerate base code (DBC) count. Drug resistance interpretation is shown for the samples preceding and following the suspected superinfection event; bullets
indicate the drugs administered in the sample interval. In Case 13, resistance against two of the drugs decreased, while resistance against one drug increased
concomitant with superinfection; in Case 14, resistance against the current drugs decreased; in the DBC+ case, resistance against both drugs increased. None of the
cases involved currently recommended drug regimens. S: Susceptible, PL: Potential low-level resistance, LL: low-level resistance, R: resistance, HR: high resistance.
In 23 of the 79 cases the sequence with high DBC count
was flanked by two sequences with low DBC counts (indi-
cating homogeneous viral populations). In one of these
cases (which we could not validate by fresh sample ampli-
fication) the sequence with high DBC count was preceded
and followed by two sequences that clustered indepen-
dently from each other. This situation is highly suggestive
of successful superinfection (strain replacement), with
the high DBC count intermediate sample representing
a transitory stage when a mixture of both strains was
present. In this patient drug resistance scores against the
drug regimen administered at the time increased consid-
erably (Table 4), and there was a temporary episode of
detectable viremia around the suspected time of superin-
fection (Additional file 7). In the remaining 22 cases where
we had samples from both before and after the sequence
with high DBC count, all sequences clustered together,
indicating that if superinfection was indeed responsible
for the sample with high DBC count, it must have been
transitory and the original strain persisted.
Discussion
HIV superinfection can lead to clinical complications [8],
intermittent viral rebounds or loss of viral control [7].
However, its population level prevalence and its clinical
implications are less well understood, with a large varia-
tion in the estimate of the frequency of superinfection in
various studies. Our study is the largest to date to esti-
mate the population level frequency of non-transient HIV
superinfection among patients under antiretroviral treat-
ment, and to assess its impact on the failure of therapy due
to drug resistance.
We developed an analysis pipeline that allowed us to
detect dual infection in large databases by leveraging
modern and reliable approaches of phylogenetic infer-
ence. This method takes advantage of the broad avail-
ability of HIV sequence data both in public and private
databases, as the detection of divergent lineages requires
a sufficiently large sample of genotypes from the under-
lying epidemic. We had rigorously analysed the choices
in the bioinformatics pipeline before we settled with the
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method that had the speed and accuracy to cope with the
large number of samples in the analysis (see Additional
file 4 and Results). The use of phylogenetic reconstruction
is justified by the overlap of the distributions of pairwise
sequence distances among sequence pairs drawn from the
same patient, from different patients of the same subtype,
and sequence pairs of polyphyletic origin from potentially
superinfected patients (Figure 3).
We note that our criteria of dual infection were
more stringent than requiring (potentially weak) non-
monophyletic clustering of a patient’s sequences. We clas-
sified the cases as dual infection if the phylogenetic tree
incorporated at least two strongly supported clusters that
each contained at least one sequence from the patient
under investigation and control sequences; furthermore,
we required a threshold number of control sequences
interspersed within the smallest subtree that included all
sequences of a patient. This procedure prevents possi-
ble false positive results arising from weakly supported
clusters, and distinguishes between transmission clusters
and superinfection cases. We also engaged in a thorough
validation of putative superinfection cases (identified on
the basis of our rigorous phylogenetic criteria) by re-
analyzing samples from a subset of the patients involved.
We thus opted for high specificity at the cost of sensitiv-
ity. We are not aware of any large scale study taking this
approach.
The initial phylogenetic analysis suggested superinfec-
tion in 107 out of 4425 patients. However, re-analysis of
stored samples for 14 of these cases confirmed only two
out of 14 cases of putative superinfection. Importantly,
we used the same bioinformatics pipeline in the original
analysis and in the validation procedure: that is, the failure
to validate most cases of putative superinfection did not
arise from the (lack of) sensitivity of the original phylo-
genetics analysis, but due to erroneous entries (sequence
or sample mix-up) in the original database. While the low
number of cases available for validation do not allow us
to derive reliable estimates on the frequency of superin-
fection in this study population, and the rigorous criteria
of our detection method may have missed some genuine
superinfection cases, the frequency is likely to be very
low. Even 107/4425 cases would imply only about 2.4%
prevalence, and most of these cases seem to have orig-
inated from sample mix-up, according to our validation
analyses. Ongoing therapy prevents superinfection with
virus strains susceptible to the current treatment of each
patient, which has probably also contributed to the low
frequency of non-transient superinfections.
Although this result may not be informative of the fre-
quency of superinfection in untreated patients, it indicates
that non-transient superinfection with strain replacement
occurs rarely during ART. In the whole analysis, we
found a single case (inferred from degenerate base code
count and the pattern of consecutive sequences) where a
superinfecting virus seems to have reduced susceptibility
against drugs administered to the patient at the time. We
have also compared the change in drug resistance scores
at the inferred superinfection events in the patients whose
results we were not able to validate by re-requencing
versus all adjacent sequence pairs of the patients with
no evidence for superinfection, and the difference was
















of polyphyletic origin 
Figure 3 Distributions of pairwise sequence distance for sequence pairs drawn from the same patient (intrapatient) or from different
patients (interpatients), and for sequence pairs of polyphyletic origin from putative superinfected patients. The distribution of the
distances for 80.000 randomly chosen sequence pairs of different patients is shown in red. Intrapatient sequence distances are shown in blue
(truncated above 200 to optimize the scale for comparison). The green overlaid histogram depicts polyphyletic sequence pairs from potentially
superinfected patients (identified from the initial phylogenetic analysis). There is no clear cutoff for the distribution of intrapatient distances.
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not significant (p=0.48, Wilcoxon test). This indicates
that, although the true number of genuine superinfec-
tion cases cannot be known in the unvalidated set, these
cases did not contribute substantially to increasing drug
resistance.
Our analysis would have been unable to detect super-
infecting virus strains that grew to low levels only or that
were outcompeted by the original strain between the sam-
ples subjected to routine sequencing. While this may have
resulted in an underestimation of superinfection in a strict
sense, such low-level or transient superinfections that do
not affect the dominant virus population can have only
limited effect on the clinical outcome. Furthermore, some
evidence indicates that superinfectionsmay occur primar-
ily in the early stages of the initial infection (reviewed
in [1]), when routine genotypic data are typically not yet
available. Such superinfections would go undetected in
our analyses; however, superinfection with highly drug
resistant viruses (that would result in subsequent therapy
failure) is expected to be rare in the absence of ART, given
the reduced replicative capacity of such strains [36] and
the overall very low frequency of such viruses in untreated
individuals [37]. Our results thus indicate that superin-
fection does not contribute substantially to the spread of
drug resistance in treated individuals and does not com-
promise the efficacy of therapy at the population level in
this European cohort.
Because our analysis depended on sequences obtained
in routine genotypic assays, the requirement for
sequences from at least two time points per patient may
have resulted in biased sampling of the study popula-
tion. A second (third etc.) genotypic assay may often be
motivated by the loss of viral suppression (to test for
the emergence of drug resistance), while patients with
suppressed virus load are less likely to be subjected to
subsequent tests. However, such a bias would actually
facilitate the detection of therapy failure due to drug
resistance transmitted by superinfection. The loss of virus
suppression would have motivated genotypic testing and
such cases would therefore have been included in our
database with high probability. Furthermore, the majority
(82%) of patients in our cohort were under ART, which
provides selective advantage to highly resistant virus
strains that can tolerate the drugs, and thereby facilitate
superinfection by such viruses. We therefore conclude
that our cohort of treated patients comprises an ideal
sentinel cohort for detecting superinfections involving
the transmission of highly resistant HIV-1 strains that
could compromise the efficacy of drug treatment. The
lack of evidence for the transmission of drug resistance
by superinfection in this population of treated patients
strongly indicates that this route of transmission does
not contribute substantially to the failure of antiretroviral
therapy in the HIV epidemic.
The lack of superinfection with drug resistant strains
is probably explained by the reduced replicative capacity
of strains with high level drug resistance [36]. The trans-
mission of multidrug-resistant HIV-1 is very rare also
in terms of primary transmission to untreated individu-
als [37]. Low replicative capacity may actually allow for
the replacement of virus strains with major drug resis-
tance mutations if superinfection with fitter less resistant
strains occurs in the absence of therapy [38,39]. In con-
trast, viral strains with limited drug resistance may have
a replicative capacity close to wild-type (as demonstrated
by some primary transmission to uninfected individuals
[40]); however, such limited drug resistance is probably
not sufficient to allow virus replication under combination
ART, and ongoing therapy probably prevented superin-
fection with partially drug resistant (or drug susceptible)
viruses in our cohort. Yet it has to be noted that major
drug resistance mutations may revert, and any remaining
minor drug resistance mutations may convey wild-type or
even increased fitness to the strain [41,42], which would
make it less likely to be replaced by superinfection.
The number of degenerate base pairs is indicative of
the co-existence of two distinct virus strains at the time
point of the sample involved [33], which may or may not
be followed by strain replacement. In our study, available
sequence data allowed us to test 23 cases with a DBC
count ≥ 45 by phylogenetic analyses of both preceding
and subsequent samples. Of these, strain replacement fol-
lowing the high DBC count sample could only be demon-
strated in a single case, which suggests that the majority
(22/23 or 96%) of superinfection events may be transient,
consistent with previous results [2]. However, transient
superinfection is unlikely to contribute to transmitted
drug resistance. We note here that a high DBC count may
result in discarding the sequence at the quality control
stage of the sequencing procedure. While there was no
systematic filtering applied at our data centres, some such
sequences may have been discarded by individual judge-
ment. Our database of routinely collected HIV-sequences
may therefore not be an unbiased sample of the whole
population with respect to degenerate base pair counts.
Our cluster based detection method did not differen-
tiate between superinfection and dual infection arising
from the simultaneous transmission of two divergent virus
strains in a single transmission event [9]. However, the
low number of transmitted virus particles [10] implies
that such simultaneous transmissions are probably rare.
Moreover, even simultaneous transmission could transmit
two divergent virus strains only if the infecting individual
harboured two strains ultimately derived from different
sources, and both at a sufficient concentration to allow
transmission. Such a combination of rare events seems
extremely unlikely, and we therefore argue that most cases
of dual infections probably reflect superinfection.
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We were able to detect superinfection (strain replace-
ment) on the basis of partial pol sequences [19,43].
Some cases of superinfection may have resulted in a new
recombinant of the resident and the superinfecting strain
that outcompeted both original strains [44]. Our analy-
sis would have detected such cases only if the region of
pol available was derived from the superinfecting virus.
Reliable detection of recombinant forms arising from
superinfection would require full genome sequencing.
Finally, we note that ourmethod revealed a high number
of samplemix-ups, and also one case where a recombinant
sequence was formed through misassembling sequence
reads from a patient’s sample and the control lab strain.
Almost all data centres were involved in at least one sam-
ple mix-up case, which sheds light on the ubiquity of the
issue. This result indicates the need for validation by re-
sequencing in the detection of superinfection, and the
need to sequence at least two samples in court cases that
use HIV sequence analysis as sources of evidence.
Conclusions
We conclude that routine genotyping data are useful for
the detection of superinfection; however, extensive vali-
dation is required to exclude sample or sequence mix-up
or contamination, which may be the most likely source
of divergent virus sequences assigned to the samples of
the same patient. Our study population (mainly therapy
experienced patients with chronic infection) was ideal for
detecting the transmission of highly drug resistant HIV-1
strains by superinfection. The lack of evidence in this pop-
ulation thus indicates that this potential route is unlikely
to contribute to therapy failure by drug resistance.
Additional files
Additional file 1: Software for evaluating phylogenetic trees with
respect to superinfection. The archive contains Ruby scripts that perform
the evaluation of a phylogenetic tree. See README in the archive for details.
Additional file 2: The distribution of the number of control
sequences clustering together with the patient’s own sequences in
those patients whose sequences failed to form amonophyletic
cluster. The number of clustering control sequences was either small
(<20) or large (>50). We hypothesized that the former case is more likely
to represent a transmission cluster, and used the criterion for the latter case
in the identification of superinfection. Phylogenetic trees were constructed
from sets of 150 sequences.
Additional file 3: Table - The distribution of HIV sequences by
subtype. Subtyping was carried out by the REGA subtyping tool [26,27].
Additional file 4: Additional Documentation - Supplementary text
describing the verification of our bioinformatics pipeline and the
approaches that did not succeed.
Additional file 5: Figure - Chart of the whole phylogeny based
analysis including the preliminary analyses.
Additional file 6: The detection of superinfection is robust with
respect to the number of control sequences in the trees.We
performed both MrBayes and RAxML analyses with tree sizes of 20, 50, 150
and (only for RAxML) 250 sequences on a subset of the data (170 patients).
Branches with a minimum support value of 60 or a minimum posterior
probability of 0.95 were retained in the trees constructed with RAxML and
MrBayes, respectively. The number of suspected patients was robust with
respect to tree size.
Additional file 7: Clinical parameters, treatment history and drug
susceptibility scores of the two confirmed superinfection cases and
of the putative superinfection case with high degenerative base
count. The archive contains Excel tables with treatment history, CD4 cell
counts, viral load measurements and drug susceptibility scores per sample.
Additional file 8: Sequence sets - Sets of case and control sequences
for the samples of the 18 validated patients. Fasta files contain the
alignments used to infer superinfection in each validated patient. The
sequences from the patient under investigation are indicated in the fasta
header lines.
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